Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IFN beta 1a TIW · 1 trial · 1 indication
A single T2 lesion was defined as an area of increased signal on a given 3-millimeters axial image that was not referable to normally hyperintense structures. New T2 lesions were those that appear in areas where on the previous scan no abnormality was detected. All T2 lesions were detected by an MRI scan.
| Arm | Type | Description |
|---|---|---|
| IFN beta 1a 44 mcg TIW + curcumin (BCM95) | EXPERIMENTAL | - |
| IFN beta 1a 44 mcg TIW + placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| IFN beta 1a 44 mcg TIW | DRUG | Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months. |
| Curcumin | DRUG | Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months. |
| Placebo | DRUG | Subjects received placebo matched to curcumin orally twice a day for 24 months. |
Inclusion Criteria: * Subjects with early diagnosis (no more than 3 years) of Relapsing Multiple Sclerosis according to the revised McDonald Criteria (2010) * Subjects currently in treatment with IFN beta-1a 44 mcg TIW, having received this treatment a minimum of 6 months and for not longer than 12...
IFN beta 1a TIW is an investigational small molecule being studied for the treatment of multiple sclerosis. It is administered three times per week. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
IFN beta 1a TIW is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this drug for multiple sclerosis, and the drug is currently in Phase 2 development.
IFN beta 1a TIW is in Phase 2 clinical development. It is an investigational drug for multiple sclerosis and has not been approved for commercial use. One Phase 2 clinical trial has been completed for this drug.
IFN beta 1a TIW has been studied in one completed Phase 2 clinical trial, registered as NCT01514370. This trial evaluated the drug in 80 participants with multiple sclerosis in Italy. The study was randomized, double-blind, and placebo-controlled.
IFN beta 1a TIW is a form of interferon beta 1a, specifically dosed three times per week. It is being investigated as a treatment for multiple sclerosis. The drug is in Phase 2 development and is not yet approved.